Analysis reveals POU2F1's role in regulating oncogenic pathways through RNA-seq and ChIP-seq data.
Figure S11. POU2F1 activates a panel of genes associated with multiple oncogenic pathways. A, The identification of candidate downstream effector genes of POU2F1 by integration of RNA-seq (blue) and ChIP-seq (red). B, Scatter plot is shown for 338 genes regulated by POU2F1 ranked by the log2 fold change (x-axis) and -log10 P-value (y-axis). C, GSEA pathway enrichment analyses of candidate effector genes regulated by POU2F1. The circle color represents the significance of enrichment, and the circle size denotes the number of genes within each pathway. The pathways enriched by TRIO, BRCA1, DEK, AGL, and NSD1 are highlighted in red. D, The correlations between POU2F1 expression and its target gene expression were evaluated in the TCGA CRC samples. The P and r values were calculated by Spearman correlation analyses. E, The correlations between POU2F1 and the genes enriched in pathways are evaluated in the two independent datasets, including the TCGA cohort and our own CRC samples. ****P < 0.0001, **P < 0.01, *P < 0.05 and r values were calculated by Spearman correlation analyses in the TCGA and our own CRC samples. ns, not significant.
No takes yet. Share an insight, caveat, or question.
Li et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: